Clinical Trial Update: Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for pyrotinib in metastatic HER2 non-amplified but HER2-mutant breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Mutant Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Peking Union Medical College | Conditions: Breast Cancer, HER2 Gene Mutation | Phase 2 | Status: UNKNOWN